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It has been known that activation of the central innate immune system or exposure to stress can disrupt balance of anti-/
proinflammatory cytokines. The aim of the present study was to investigate the role of pro- and anti-inflammatory cytokines in
the modulation of depressive-like behaviors, the hormonal and neurotransmitter systems in rats.We investigated whether centrally
administered IL-1𝛽 is associatedwith activation ofCNS inflammatory pathways and behavioral changes andwhether treatmentwith
IL-4 could modulate IL-1𝛽-induced depressive-like behaviors and central neurotransmitter systems. Infusion of IL-4 significantly
decreased IL-1𝛽-induced anhedonic responses and increased social exploration and total activity. Treatment with IL-4 markedly
blocked IL-1𝛽-induced increase in PGE
2
and CORT levels. Also, IL-4 reduced IL-1𝛽-induced 5-HT levels by inhibiting tryptophan
hydroxylase (TPH) mRNA and activating serotonin transporter (SERT) in the hippocampus, and levels of NE were increased by
activating tyrosine hydroxylase (TH)mRNAexpression.These results demonstrate that IL-4may locally contribute to the regulation
of noradrenergic and serotonergic neurotransmission and may inhibit IL-1𝛽-induced behavioral and immunological changes. The
present results suggest that IL-4 modulates IL-1𝛽-induced depressive behavior by inhibiting IL-1𝛽-induced central glial activation
and neurotransmitter alterations. IL-4 reduced central and systemic mediatory inflammatory activation, as well as reversing the
IL-1𝛽-induced alterations in neurotransmitter levels. The present findings contribute a biochemical pathway regulated by IL-4 that
may have therapeutic utility for treatment of IL-1𝛽-induced depressive behavior and neuroinflammation which warrants further
study.
1. Introduction
Cytokines have been implicated in the evolution of several
neuropathological states, including depressive disorders. Like
stressors, whichmay engender features of depressive disorder
in rodents, the systemic administration of proinflammatory
cytokines such as interleukin-1𝛽 (IL-1𝛽) and tumor-necrosis
factor-𝛼 (TNF-𝛼) increases hypothalamic-pituitary-adrenal
(HPA) activity [1, 2]. Additionally, cytokines increase mono-
amine turnover in several limbic sites [3–5]. Another impor-
tant cytokine is IL-4, which is a kind of anti-inflammatory
cytokine. Although it is normally not synthesized at high lev-
els in the brain, it is strongly expressed during brain injury or
infection [6]. Several studies reported that anti-inflammatory
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cytokines have the ability to suppress the synthesis of IL-1,
TNF, and other cytokines in peripheral immune and non-
immune cells [7]. However, the different regulatory functions
of cytokines and the effect on behavioral changes and mono-
amine levels in animal models of depression are currently
under investigation.
In the present study, we aimed to investigate the role of
pro- and anti-inflammatory cytokines in the modulation of
depressive-like behaviors and the hormonal and neurotrans-
mitter systems. We sought to determine (1) whether cen-
trally administered IL-1𝛽 is associated with activation of
CNS inflammatory pathways and depressive-like behavioral
changes using the tail suspension test, social interaction,
and sucrose intake; (2) whether IL-1𝛽-induced behavioral
changes are associated with peripheral inflammatory path-
ways, prostaglandin E
2
(PGE
2
), or corticosterone (CORT);
and (3) whether treatment with IL-4 modulates IL-1𝛽-indu-
ced depressive-like behaviors and central neurotransmitter
systems by measuring the concentration of serotonin (5-HT)
and norepinephrine (NE) after IL-1𝛽 intracerebroventricular
(i.c.v.) injection.
2. Materials and Methods
2.1. Animals. All the experimental procedures performed on
the animals were conducted with the approval of the Ethics
Committee of Kyung Hee University and in accordance with
the US National Institutes of Health “Guide for the Care and
Use of Laboratory Animals” (NIH Publication number 80-
23, revised 1996). Sprague-Dawley rats (Orient Animal Corp.,
Kyunggi-do, Korea) that weighed 220–240 g each were used
for the experiments. The male rats were group-housed (three
per cage) under a reversed light-dark cycle (light on from
08:00 to 20:00 hr). The room temperature was 20∼25∘C and
the humidity was 30 ± 5%. The rats had free access to food
and water. All the rats were handled daily for at least a week
prior to the experiment.
2.2. Surgery and Intracranial Drug Injections. Rats were
anesthetized with sodium pentobarbital (50mg/kg, i.p.) and
placed in a stereotaxic apparatus. The skull was firmly placed
in the apparatus and the scalp was shaved and cleaned with
betadine. An incision was made through the skin and muscle
to expose the skull and the skin was then retracted. Guide
cannulae, 22-gauge, aimed at terminating 1mm above the 3rd
ventricle (AP-0.8mm, ML-0.5, DV-6mm), were stereotaxi-
cally implanted using dental cement with three screws to
secure them to the scull. The cannulae were lowered in the
sagittal plane following retraction of the superior sagittal
sinus. A 28-gauge stainless steel obturator which extended
1mm beyond the end of the guide cannula was then inserted.
Following surgery, sterile penicillin (1 cc/kg, Durapen) was
given to all rats. The rats were allowed 7 days to recover from
surgery before testing.
Intracerebroventricular (i.c.v) infusion of rat recombi-
nant IL-1𝛽 (Sigma) or IL-4 (Sigma) was performed into the
ventricle through the guide cannula over a time course of
5min using a 2 uL/min syringe pump (CMA 102, CMAMic-
rodialysis, Solna, Sweden) connected to PE-10 tubing (Plastic
One, Pennsylvania, USA) precut to the appropriate length.
The injector (Plastic One) was left in place for another 2 hr
to allow for drug diffusion. The injector extended 1.0mm
below the end of the guide cannula into the ventricle. All the
employed coordinates were from the atlas of Paxinos et al. [8].
Rats received microinjections of rat recombinant IL-1𝛽
at the 3rd ventricle (100 ng) or autologous CSF (CSF group,
𝑁 = 5) as healthy control group. Two hours later the animals
injected with IL-1𝛽were given i.c.v. injections of either 100 ng
(𝑁 = 6) or 200 ng (𝑁 = 6) of IL-4 or saline (vehicle group,
𝑁 = 6) in the volume of 0.5 uL.
2.3. Sucrose Intake and Body Temperature. The animals were
transported to a testing room, to which they were allowed
to adapt for 1 hr prior to testing. For the sucrose intake test,
subjects were trained to consume 1% sucrose solution prior to
the start of the experiment. They were exposed to 1% sucrose
solution for a 48 h period in their home cage without any
food or water available. Testing took place once, between
14:00 and 15:00 hr. Prior to the test, animals were food and
water deprived for 20 hr. Sucrose solution consumption was
recorded by reweighing preweighed bottles of test solution
[9]. Body temperature was measured 7 hours after IL-1𝛽 i.c.v.
injection.
2.4. Tail Suspension Test (TST). A short piece of paper
adhesive tape (about 6 cm) was attached along half the length
of the tail (about 3 cm).The free end of the adhesive tape was
attached to a 30 cm long rigid tape (made from the paper tape
folded several times) which was attached to a seesaw lever
inked to a spring strain gauge that activated the hand of a
spring balance.The animal was surrounded by white-painted
wooden enclosed arms (𝐻: 54 cm,𝑊: 30 cm, and 𝐷: 47 cm),
such that the rat’s head was about 10 cm above the floor. Rats
were observed for 6min. As recently pointed out byMayorga
and Lucki [10], one of the confounding factors in the tail
suspension test is tail-climbing behavior. The tail-climbing
periods tend to be scored as immobility by a mechanical
device although they clearly constitute avoidance behavior.
2.5. Social Exploration. Behavioral observations were carried
out during the dark phase of the cycle, under red light illumi-
nation. Rats were introduced into the home cage of the test
animal for 5min [11]. One day before the experiment, baseline
social exploration was assessed. Therefore, the total time
spent by the experimental rat in social exploration during the
5min session was recorded by a skilled observer blinded to
the experimental conditions. Notably, the total time in con-
tact with the juvenile, but only contact that was directly initia-
ted by the experimental rat anddefined as “social exploration”
(e.g. anogenital and body sniffing, following, and grooming
of the juvenile), was recorded.Thus, leaning against the juve-
nile or incidental side-by-side touching was not counted.
2.6. Corticosterone (CORT) andProstaglandin E
2
(PGE
2
)Mea-
surement. After the behavior test, we collected blood samples
from the rats. The total concentration of CORT and PGE
2
was measured by an ELISA kit (DuoSet ELISA Development
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System, R&DSystems, Inc.,Minneapolis,MN,USA). Cardiac
blood was collected just prior to sacrificing the rats. The
blood was centrifuged for 15 minutes at 1000×g within 30
minutes of collection.The samples were immediately assayed
or stored at ≤−60∘C. All the reagents, working standards,
and samples were prepared.The excess microplate strips were
removed from the plate frame and returned to the foil pouch
containing the desiccant pack and then the pouch was sealed.
All of the samples or standards (100 uL) were added to the
appropriately labeled wells and 50 uL of conjugated serum
was placed into all of the wells except for the nonspecific
binding wells and the total count wells. CORT or PGE
2
(50 uL) was added to all of the wells. All of the wells were
incubated for two hours at room temperature on a horizontal
orbital microplate shaker (0.12󸀠󸀠 orbit) set at 500 ± 50 rpm.
Each well was washed three times with wash buffer. After
the last washing, any remaining wash buffer was removed by
aspirating or decanting it. 5 uL of CORT or PGE
2
conjugate
and 200 uL of p-nitrophenyl phosphate-substrate were added
to all of the wells. The well was incubated for 1 hour at room
temperature (without shaking). Next, 50 uL of Stop Solution
was added to each well. Using a microplate reader, the optical
density of each well was immediately determined.The absor-
bance was read at 450 nm and 550 nm, and the sample values
were calculated from a standard curve.
2.7. Glial Fibrillary Acidic Protein (GFAP) Measurement.
Animals were sacrificed after behavioral test and then brain
tissues were collected.The total concentration of GFAP in the
hypothalamus was measured by an ELISA kit (ELISA Devel-
opment System, USCN Life Science, Inc., Huston, TX, USA).
Thebrain protein sampleswere immediately assayed or stored
at ≤−70∘C. All the reagents, working standards, and samples
were prepared. The protein of brain was extracted by RIPA
buffers. The excess microplate strips were removed from the
plate frame and returned to the foil pouch containing the des-
iccant pack and then the pouch was sealed. All of the samples
or standards (100 uL) were added to the appropriately labeled
wells and incubated for 2 hours at 37∘C. Detection reagent A
was added to each well followed by incubation for one hour at
room temperature on a horizontal orbital microplate shaker
(0.12󸀠󸀠 orbit) set at 500 ± 50 rpm. Each well was washed three
times with wash buffer. After the last washing, any remaining
wash buffer was removed by aspirating or decanting it.
Following this, 100 uL of detection reagent B was added to
each well and the plate was incubated for 30 minutes at room
temperature (without shaking). Each well was washed three
times with wash buffer. After the last washing, any remaining
wash buffer was removed by aspirating or decanting it. Next,
100 uL of substrate working solution was added to each well
and incubated for 5–10 minutes at 37∘C. Using a microplate
reader, the optical density of each well was immediately
determined.The absorbance was read at 450 nm and 550 nm,
and the sample values were calculated from a standard curve.
2.8. Serotonin (5-HT) andNorepinephrine (NE)Measurement.
Thetotal concentration of 5-HT andNE in the brainwasmea-
sured by an ELISA kit (ELISA Development System, Labor
Diagnostika Nord, Inc., Minneapolis, MN, USA). First, all
samples were acylated in acylation plate for 24 hr. Acylated
sampleswere transferred into a 5-HT antibody coated 96-well
plate, 25 uL of 5-HT antiserum was added to each well, and
the plate was incubated for 20 hr. Each well was washed three
times with wash buffer. After the last washing, any remaining
wash buffer was removed by aspirating or decanting it. Fol-
lowing this, 100 uL of enzyme conjugate was added and incu-
bated for 20min at RT. Next, 100 uL of Stop Solution was
added to eachwell. Using amicroplate reader, the optical den-
sity of each well was immediately determined. The absorba-
ncewas read at 450 nm, and the sample valueswere calculated
from a standard curve.
2.9. Tryptophan Hydroxylase (TPH), Serotonin Transporter
(SERT), Tyrosine Hydroxylase (TH), and Norepinephrine Tra-
nsporter (NET) mRNAMeasurement by RT-PCR. Total RNA
was isolated using TRIzol reagent (Invitrogen Co., Carlsbad,
CA, USA) according to the manufacturer’s instructions.
Reverse transcription was performed with 2 ng of total RNA
using PrimeScript RTase (Takara Bio Inc., Shizuoka, Japan)
and random hexamer primers. The subsequent amplification
of GAPDH, SERT, NET, TH, and TPH was done by PCR in
a total volume of 20 uL containing 0.5U of rTaq polymerase
(Takara Bio Inc.) and 10 pmol of a specific primer set. The
primers used were as follows: for GAPDH, forward 5󸀠-TGA
TGC TGG TGC TGA GTA AGT CGT-3󸀠, reverse 5󸀠-TTG
TCA TTG AGA GCA ATG CCA GCC-3󸀠; for SERT, forward
5󸀠-CCACCTTCCCATACATTGT-3󸀠, reverse 5󸀠-CTGTCT
CCAAGAGTT TCTGC-3󸀠; for NET, forward 5󸀠-GGAGTG
GGC CTA TGC TGT GAT-3󸀠, reverse 5󸀠-GTC ATG GAT
CCC ACT GCT CT-3󸀠; for TH, forward 5󸀠-GGA GCT GAA
GGC TTA TGG TG-3󸀠, reverse 5󸀠-CCAT TGA AGC TCT
CGG ACA CA-3󸀠; and for TPH, forward 5󸀠-GCT GAA CAA
ACT CTA CCC AAC-3󸀠, reverse 5󸀠-TTC CCG ATA GCC
ACA GTA TT-3󸀠. The reaction conditions were as follows:
5min at 95∘C followed by 24–32 cycles of 94∘C for 30 s, 52–54
for 40 s, and 72∘C for 1min with a final extension at 72∘C for
7min.The amplified productswere separated on a 2%agarose
gel and stained with ethidium bromide. The results were
analyzed using the image analysis program CoreBio i-MAX
TM (CoreBio Co., Seoul, Korea).
2.10. Data Analysis. All the results from behavioral, bio-
chemical, and immunological tests are expressed as means ±
standard error of the mean (SEM). Statistical analyses were
performed using SPSS 15.0 software (SPSS Inc., Chicago,
IL). One-way analysis of variance (ANOVA) was performed
in order to identify statistically significant changes in the
biochemical and behavioral data, followed by the post hoc
LSD test. Normality of distribution and equality of variances
were confirmed using these tests. 𝑃 values ≤ 0.05 were
considered statistically significant.
3. Results
3.1. IL-4 Attenuated IL-1𝛽-Induced Body Temperature and
Anhedonia Response. Even though IL-1𝛽 can be a pyrogen
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Figure 1: Effect of IL-4 injection 2 hours after injection of i.c.v. IL-1𝛽 on body temperature (a), sucrose intake (b), social interaction (c), and tail
suspension test (d). Treatment effects were assessed on the mean activity (counts) during 5 minutes. The rats were randomly assigned to four
groups of six individuals each as follows: CSF group receivedmicroinjections of CSF; IL-1𝛽 group receivedmicroinjections of rat recombinant
IL-1𝛽 at the 3rd ventricle; IL-4 groups received microinjections of rat recombinant IL-4 at the 3rd ventricle. Each value represents the mean ±
SEM. #𝑃 < 0.05, ##𝑃 < 0.01, and ###𝑃 < 0.001 compared to the CSF and ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 compared to the IL-1𝛽
treated group. Control, 𝑛 = 5; IL-1𝛽, 𝑛 = 5; IL-4 100 ng, 𝑛 = 5; IL-4 200 ng, 𝑛 = 5.
itself, at the dose used here and with no provision of addi-
tional ambient warmth, we only observed a modest elevation
of body temperature of 1∘C or less after IL-1𝛽 injection in rats.
After 6 hours, the rat’s body temperature returned to the base-
line level (Figure 1(a)).
Considering that anhedonia is one of the core symptoms
of depression, the effects of IL-1𝛽 administration with a suc-
rose intake test were investigated. Figure 1(b) shows that IL-
1𝛽 (100 ng/site, i.c.v.) administration produced an anhedonic
effect as evaluated by the decrease in sucrose intake as
compared to the CSF group (F
3,22
= 3.1, 𝑃 < 0.05). Moreover,
sucrose intake in IL-4 (i.c.v.) treated rats that were adminis-
tered IL-1𝛽 (100 ng/site, i.c.v.) 2 hr later was restored, showing
that the anhedonic effects of this cytokine are sensible to anti-
inflammatory cytokine treatment. The LSD test results indi-
cate significantly decreased depressive behavior in the IL-4
groups compared to that of the vehicle group (𝑃 < 0.05).
3.2. IL-4 Attenuated IL-1𝛽-Induced Reduction in Social Inter-
action. Figure 1(c) presents the mean number for each group
in which rats did active investigation, anogenital sniffing,
wrestling, following, licking, and grooming of a juvenile
stimulus animal in their home cage during a 5min test. IL-
1𝛽 administration to the rats led to a robust suppression of
social interaction. In particular, active behaviors on the social
exploration test were significantly different when compared
among the groups (wrestling: F
3,22
= 8.9, 𝑃 < 0.01; following:
F
3,22
= 6.5, 𝑃 < 0.01; grooming: F
3,22
= 15.2, 𝑃 < 0.001).
The LSD test results indicate markedly decreased social
exploration (following and grooming) behavior in the vehicle
group as compared to that of the CSF group. However, after
IL-4 treatment, rats showed significant increase in the sum
of social behaviors (following and grooming) and increase in
wrestling number compared to the vehicle group.
3.3. IL-4 Attenuated IL-1𝛽-Induced Depressive Behavior. We
evaluated the ability of rats to cope with a stressful and
inescapable situation (learned helplessness) with a tail sus-
pension test (TST). As shown in Figure 1(d), the animals dis-
playing increased immobilization periods were considered to
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have increased helplessness, which is a sign of depressive-like
behavior (F
3,22
= 5.4, 𝑃 < 0.05). When tested with the TST,
the vehicle treated rats showed more increased immobility
time during the 5min test than the CSF group. However,
after IL-4 treatment, rats displayed significantly decreased
immobility time in the TST (𝑃 < 0.05).
3.4. IL-4 Altered IL-1𝛽-Induced Increases in Plasma CORT.
Plasma levels of CORT in the IL-1𝛽 treated group were
significantly elevated 6 hr after i.c.v. injection compared with
the CSF group (F
3,22
= 15.0, 𝑃 < 0.001; Figure 2(a)). The LSD
test results indicated significantly increased serum levels of
CORT in the vehicle group compared to the CSF group (𝑃 <
0.01). However, the treatment of IL-4 resulted in markedly
decreased serum levels of CORT compared to the vehicle
group (𝑃 < 0.001).
3.5. IL-4 Altered IL-1𝛽-Induced Increases in Plasma PGE
2
.
Plasma levels of PGE
2
in the vehicle group were significantly
elevated 6 hr after i.c.v. injection compared with the CSF
group (F
3,22
= 3.2, 𝑃 < 0.05; Figure 2(b)). The LSD test
results indicated significantly increased serum levels of PGE
2
in the vehicle group compared to the CSF group (𝑃 < 0.05).
However, the treatment of IL-4 led to markedly decreased
serum levels of PGE
2
compared to the vehicle group (𝑃 <
0.05).
3.6. IL-4 Altered IL-1𝛽-Induced 5-HT Level and SERT and
TPH Expression in the Brain Regions. Central 5-HT level in
brain regions was changed after i.c.v. IL-1𝛽 infusion that has
been linked to major depression (Figure 3(a)). In particular,
5-HT levels in the prefrontal cortex and hippocampus were
increased by the IL-1𝛽 treatment (F
3,22
= 6.0 and 13.1, 𝑃 <
0.01). However, both IL-4 treated groups showed appreciably
decreased 5-HT levels in the hippocampus and cortex.Within
the hypothalamus, 5-HT levels were not affected by the cyto-
kine treatment.
Level of SERT in the vehicle group was significantly
increased in the cortex after IL-1𝛽 injection compared with
the CSF group (F
3,22
= 8.2, 𝑃 < 0.01), whereas levels of SERT
in the hippocampus were reduced (F
3,22
= 8.4, 𝑃 < 0.01).
Treatment with IL-4 markedly potentiated SERT levels in the
prefrontal cortex and hippocampus compared with the vehi-
cle group (F
3,22
= 8.2, 𝑃 < 0.01).
In several brain regions (the prefrontal cortex and
hippocampus), expression of tryptophan hydroxylase was
increased by IL-1𝛽 injections (F
3,22
= 6.9, 𝑃 < 0.01). Both IL-
4 treated groups markedly decreased TPH levels in the pre-
frontal cortex compared with the vehicle group (Figure 3(b)).
3.7. IL-4 Increased i.c.v. IL-1𝛽-Induced NE Level and TH and
NET Expression in the Brain Regions. Central NE level in
brain regions was changed after i.c.v. IL-1𝛽 infusion that
has been linked to major depression (Figure 4(a)). In several
brain regions (the prefrontal cortex, hippocampus, and hypo-
thalamus), expression of NE was altered by IL-4 treatment
(F
3,22
= 6.9 and 32.3, 𝑃 < 0.01, 𝑃 < 0.01, resp.). Both
IL-4 treated groups markedly increased the NE level in the
prefrontal cortex and hippocampus compared to the vehicle
group. However, NE levels in the hypothalamus were not
affected by cytokine treatment.
Expression of TH in the vehicle group was significantly
increased in the cortex after IL-1𝛽 injection compared with
the CSF group (F
3,22
= 6.9, 𝑃 < 0.01), whereas expression of
TH in the hippocampus was reduced (F
3,22
= 6.5, 𝑃 < 0.01).
Treatment with IL-4 markedly potentiated TH expressions in
the prefrontal cortex and hippocampus compared with the
vehicle group (F
3,22
= 7.2, 𝑃 < 0.01).
However, the NET level in the limbic regions was not
affected by IL-4 treatment (Figure 4(b)).
3.8. IL-4 Altered IL-1𝛽-Induced Increases in GFAP. Levels of
GFAP in the vehicle group were significantly elevated 6 hr
after i.c.v. injection compared with the CSF group (F
3,22
= 4.2,
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Figure 3: (a) Effect of IL-4 injection 2 hours after injection of i.c.v. IL-1𝛽 on 5-HT concentration. Mean (±SEM) concentrations (nanogram
per gram) of 5-HT within the mPFC, hippocampus, and hypothalamus among rats. Each value represents the mean ± SEM. #𝑃 < 0.05,
###
𝑃 < 0.001 compared to the CSF and ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 compared to the IL-1𝛽 treated group. Control, 𝑛 = 5; IL-1𝛽,
𝑛 = 5; IL-4 100 ng, 𝑛 = 5; IL-4 200 ng, 𝑛 = 5. (b) Effect of IL-4 injection 2 hours after injection of i.c.v. IL-1𝛽 on SERT and TPHmRNA levels
in the brain. Values are means ± SEM. Relative % GAPDH of SERT and TPH mRNA levels within the mPFC and hippocampus among rats.
Each value represents the mean ± SEM. ###𝑃 < 0.001 compared to the CSF, ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 compared to the IL-1𝛽
treated group. Control, 𝑛 = 5; IL-1𝛽, 𝑛 = 5; IL-4 100 ng, 𝑛 = 5; IL-4 200 ng, 𝑛 = 5.
𝑃 < 0.05; Figure 5). The LSD test results indicated signifi-
cantly increased levels of GFAP in the vehicle group com-
pared to the CSF group (𝑃 < 0.01). However, the treatment
of IL-4 led tomarkedly decreased serum levels of GFAP com-
pared to the vehicle group. We also examined the levels of
GFAP in the cortex and hippocampus but did not show
changes among groups.
4. Discussion
The goal of this experiment was to examine the behav-
ioral and biochemical changes induced by anti-inflammatory
cytokine IL-4 after IL-1𝛽 administration.We have shown that
centrally administered IL-4 reduced depressive-like behav-
iors that were induced by i.c.v. IL-1𝛽. Additionally, central
administered IL-4 normalized the metabolism of multi-
ple hormones and neurotransmitters, including CORT, the
inflammatory mediator PGE
2
, and 5-HT and NE.
Lending clear support to the hypothesis that centrally
injected IL-1𝛽 can cause depressive behaviors, rats adminis-
tered IL-1𝛽 i.c.v. demonstrated significant changes in depres-
sive-like behavior. Bluthe´ et al. [12] observed that the increa-
ses of IL-1𝛽 in the serumwere strongly relatedwith the induc-
tion of a depressive-like behavior in rats. Systemic lipopoly-
saccharide (LPS) administration also increased the expres-
sion of IL-1𝛽. In this study, administration of IL-1𝛽 produced
a decrease in total activity, social exploration, and anhedonic
behavior. In a number of previous experiments, 100 ng
doses of IL-1𝛽 have been shown to reduce sweetened milk
consumption [13].
The anti-inflammatory action of IL-4 is well documented
both in vitro and in vivo. IL-4 attenuates the activation of var-
ious immunocompetent cells, including neutrophils, mono-
cytes, and macrophages, by limiting the production of proin-
flammatory cytokines [14–16], and it decreases production of
PGE
2
[17]. Exposure of murine peritoneal macrophages to
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Figure 4: (a) Effect of IL-4 injection 2 hours after injection of i.c.v. IL-1𝛽 on NE concentration. Mean (±SEM) concentrations (picogram per
gram) of NE within the mPFC, hippocampus, and hypothalamus among rats. Each value represents the mean ± SEM. #𝑃 < 0.05 compared
to the CSF and ∗𝑃 < 0.05, ∗∗∗𝑃 < 0.001 compared to the IL-1𝛽 treated group. Control, 𝑛 = 5; IL-1𝛽, 𝑛 = 5; IL-4 100 ng, 𝑛 = 5; IL-4 200 ng,
𝑛 = 5. (b) Effect of IL-4 injection 2 hours after injection of i.c.v. IL-1𝛽 on NET and TH mRNA levels in the brain. Values are means ± SEM.
Relative % GAPDH of NET and TH mRNA levels within the mPFC and hippocampus among rats. Each value represents the mean ± SEM.
#
𝑃 < 0.05 compared to the CSF and ∗∗𝑃 < 0.01, compared to the IL-1𝛽 treated group. Control, 𝑛 = 5; IL-1𝛽, 𝑛 = 5; IL-4 100 ng, 𝑛 = 5; IL-4
200 ng, 𝑛 = 5.
murine IL-4 for 16 hr before stimulation with IL-1𝛽 induced
production of PGE
2
. In addition, IL-1𝛽 is a potent modulator
of corticotrophin-releasing hormone which produces height-
ened hypothalamic-pituitary-adrenal axis activity character-
ized by increases in adrenocorticotropic hormone (ACTH)
and CORT, both of which are reported to be generally ele-
vated in major depression. A proinflammatory effect of IL-
1 observed in vitro is induction of PGE
2
synthesis in fibro-
blasts [18]. Consistent with previous studies, injection of IL-
1𝛽 significantly increased level of CORT and PGE
2
in the
serum. These results showed that IL-1𝛽 i.c.v. quickly destro-
yed peripheral immunological homeostasis. However, several
cytokines, such as IL-1𝛼, transforming growth factor-𝛽, IL-
4, and IL-10, have been described as regulating COX-2
induction and PGE
2
production [19, 20]. Also, observed in
vitro was suppression of IL-1𝛽-induced PGE
2
generation in
mouse osteoblastic cells by IL-4, a Th
2
cell-derived cytokine.
Our data reinforce this inhibitory effect of IL-4 on IL-1𝛽-
induced PGE
2
expression by demonstrating the capacity of
this cytokine to downregulate IL-1𝛽-induced delayed PGE
2
and CORT biosynthesis in rats.
Glial fibrillary acidic protein (GFAP) is the intermediate
filament protein most commonly used as a marker for the
identification of astrocytes in vivo and in vitro and is known
to be elevated following neuroinflammatory-induced glial
activation. It is characterized by immunogenic determina-
tions [21]. In this study we examined the change of GFAP
levels in the hypothalamus. Astrocytes serve as one of the
representatives of the immune system in the brain, protecting
the brain from invading microorganisms. They are primarily
responsible for the inflammatory reaction in response to
brain damage. In this study, it is possible that IL-1𝛽-induced
increases in GFAP may be compensatory mechanisms to
repair a decrease of neuroinflammation responses after IL-
4 injection [22]. One limitation of the present studies is that
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𝑛 = 5; IL-1𝛽, 𝑛 = 5; IL-4 100 ng, 𝑛 = 5; IL-4 200 ng, 𝑛 = 5.
only a change of GFAP was examined, since many of these
factors would be expected to show the regulatory effect of
neuroinflammation-behavior-GFAP activation.Thenext step
will be to evaluate the activation of microglia and anatomi-
cally specify these changes at the protein level.
In conclusion, IL-4 has antidepressive effects by reducing
immobility time on TST and increasing SERT, NE, and
TH mRNA levels in the brain regions. The study provides
evidence that IL-4 plays an important role in modulating the
hormonal and neurotransmitter regulatory systems that are
relevant for IL-1𝛽-induced depressive behaviors. The cross
talk between these systems, mediated by IL-4, may become a
target for novel antidepressant therapies. Moreover, the acute
administration of IL-1𝛽 can be a reliable inflammatory pre-
clinical model of depressive-like behavior that is sensitive to
antidepressant treatment that may be useful to test potential
new antidepressant drugs. In the future, studies of molecules
that might represent a link of the modulation of neural,
endocrine, and immune systems are extremely important to
further understand the etiology of depression.
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